ophthalmology

News

Boehringer Ingelheim has started a phase 2 trial of a drug that could offer the first oral drug for geographic atrophy, a major cause of sight loss.

News

Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive.

News

After its lead wet AMD drug failed a phase 3 trial, Opthea may have to make massive repayments to investors that would threaten its viability.

News

Neurotech Pharma's cell therapy Encelto has become the first FDA-approved therapy for idiopathic macular telangiectasia type 2.

News

Astellas has shored up the competitive profile of Izervay for eye disorder geographic atrophy, getting FDA approval for extended treatment.

News

The renaissance of Roche's refillable ophthalmic implant Susvimo has continued with FDA approval for use in patients with diabetic macular oedema.